Guido Putignano

Dr. Guido Putignano


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GPGuido Putignano
Guido Putignano
SRSamuel Ruipérez-Campillo
Samuel Ruipérez-Campillo
ZYZhou Yuan
Zhou Yuan
JMJosé Millet
José Millet
SGSara Guerrero-Aspizua
Sara Guerrero-Aspizua
Background: The field of synthetic biology aims to engineer living organisms for specific therapeutic applications, with CAR-T cell therapy emerging as a groundbreaking approach in cancer treatment due to its potential for flexibility, specificity, predictability, and controllability. CAR-T cell therapies involve the genetic modification of T cells to target tumor-specific antigens. However, challenges persist because the limited spatio-temporal resolution in current models hinders the therapy’s safety, cost-effectiveness, and overall potential, particularly for solid tumorsMain body: This manuscript explores how mathematical models and computational techniques can enhance CAR-T therapy design and predict therapeutic outcomes, focusing on critical factors such as antigen receptor functionality, treatment efficacy, and potential adverse effects. We examine CAR-T cell dynamics and the impact of antigen binding, addressing strategies to overcome antigen escape, cytokine release syndrome, and relapse.Conclusion: We propose a comprehensive framework for using these models to advance CAR-T cell therapy, bridging the gap between existing therapeutic methods and the full potential of CAR-T engineering and its clinical application.

23 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BGBarbara Giordani Barbara Giordani
Barbara Giordani Barbara Giordani
LPLuigi Pirtoli
Luigi Pirtoli
GPGuido Putignano
Guido Putignano
Antonio GiordanoAntonio Giordano
Antonio Giordano
DMDaniela Marotto
Daniela Marotto
Giovanni BaglioGiovanni Baglio
Giovanni Baglio
Background: Cancer represents a major concern in rheumatology. Epidemiological studies have demonstrated associations between rheumatic conditions and increased cancer risk at specific sites. However, comprehensive Italian epidemiological data on this association remain lacking. Methods: We conducted a nationwide retrospective cohort study using Italian Hospital Discharge Records from patients hospitalized between 1 January and 31 December 2018, with follow-up until 31 December 2023. Adult patients with Immune-mediated inflammatory diseases (IMID), including rheumatoid arthritis (RA) and diffuse diseases of connective tissue (DDCT), were the exposed group. The unexposed group included patients with primary diagnoses of injury and poisoning, with no IMID history. We used multivariable logistic regression models to assess cancer association, adjusting for demographics, geography, time of follow-up and comorbidities. Results: We included 54,896 IMID patients (exposed) and 301,126 unexposed. During the five-year follow-up, the IMID group was significantly associated with cancer (adjusted OR 1.32, 95% CI 1.27–1.38; p < 0.001). The ORadj decreased over time, from 1.83 (p < 0.001) in year one to 1.20 (p < 0.001) from the fifth year onward. Significant association with lung cancer (ORadj 1.74; p < 0.001), leukemia and lymphoma (ORadj 1.98; p < 0.001), bladder (ORadj 1.48; p < 0.001) and melanoma (ORadj 1.48; p = 0.009) were observed in the IMID group. DDCT patients showed an overall higher cancer risk (ORadj 1.53, p < 0.001) than RA patients (ORadj 1.20, p < 0.001). Conclusions: This first nationwide Italian study confirms an association with cancer in IMID patients, with the highest association in the first year post-diagnosis. The temporal decrease in cancer risk generates the hypothesis that inflammation, rather than medication, may be the primary driver. These findings support enhanced cancer surveillance in IMID patients, particularly during the first year after diagnosis.

13 October 2025 in Nature Reviews Bioengineering
Verified
Journal Article
Closed access
PDF file
LCLaura Castro-Aldrete
Laura Castro-Aldrete
MEMelanie Einsiedler
Melanie Einsiedler
CCCarla Cuní-López
Carla Cuní-López
QVQuentin Vanhaelen
Quentin Vanhaelen
ASAntonia Silvestri
Antonia Silvestri
ACAntonella Santuccione Chadha
Antonella Santuccione Chadha


8 September 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GPGuido Putignano
Guido Putignano
SRSamuel Ruipérez-Campillo
Samuel Ruipérez-Campillo
ZYZhou Yuan
Zhou Yuan
JMJosé Millet
José Millet
SGSara Guerrero-Aspizua
Sara Guerrero-Aspizua